Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Short Interest Update

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 222,300 shares, a growth of 67.1% from the September 15th total of 133,000 shares. Based on an average daily trading volume, of 458,600 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.4% of the shares of the company are short sold.

SNSS opened at $0.70 on Tuesday. The firm has a market cap of $65.20 million, a P/E ratio of -0.93 and a beta of 2.74. Sunesis Pharmaceuticals has a 1-year low of $0.20 and a 1-year high of $1.77. The company has a 50 day simple moving average of $0.73 and a two-hundred day simple moving average of $0.89. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.27 and a quick ratio of 2.27.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.01. Equities analysts anticipate that Sunesis Pharmaceuticals will post -0.41 earnings per share for the current year.

Several analysts recently issued reports on the stock. HC Wainwright restated a “hold” rating and set a $1.50 target price on shares of Sunesis Pharmaceuticals in a research report on Friday, August 9th. ValuEngine upgraded shares of Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research lowered shares of Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 10th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Sunesis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $2.92.

Institutional investors and hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its position in shares of Sunesis Pharmaceuticals by 42.7% in the second quarter. Wells Fargo & Company MN now owns 1,341,151 shares of the biopharmaceutical company’s stock worth $975,000 after purchasing an additional 401,193 shares during the period. A.R.T. Advisors LLC boosted its position in shares of Sunesis Pharmaceuticals by 33.9% during the second quarter. A.R.T. Advisors LLC now owns 98,842 shares of the biopharmaceutical company’s stock worth $72,000 after acquiring an additional 25,042 shares during the last quarter. Algert Global LLC boosted its position in shares of Sunesis Pharmaceuticals by 226.1% during the second quarter. Algert Global LLC now owns 67,014 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 46,464 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Sunesis Pharmaceuticals during the second quarter worth $1,018,000. Finally, Northern Trust Corp boosted its position in shares of Sunesis Pharmaceuticals by 54.8% during the second quarter. Northern Trust Corp now owns 165,769 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 58,653 shares during the last quarter. Institutional investors and hedge funds own 32.88% of the company’s stock.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Featured Story: Municipal Bonds

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.